Replies to post #63069 on BioRestorative Therapies Inc (BRTX)

[I ll be back]

Correct, the best part!

In November of this year, we closed on a $23 million capital raise and concurrently listed our securities on the Nasdaq Capital Market. This is a very significant development as we are now fully funded to complete our Phase 2 trial for our lead clinical candidate, BRTX-100, for the treatment of chronic lumbar disc disease (CLDD.)